$172.1 M

NEOS Mkt cap, 16-Aug-2018
Neos Therapeutics Net income (Q2, 2018)-29.6 M
Neos Therapeutics EBIT (Q2, 2018)-25.8 M
Neos Therapeutics Cash, 30-Jun-201818.3 M
Neos Therapeutics EV213.7 M

Neos Therapeutics Revenue

Neos Therapeutics revenue was $9.15 m in FY, 2016 which is a 141.4% year over year increase from the previous period.

Embed Graph

Neos Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016

Revenue

3.8 m9.2 m

Revenue growth, %

141%

Cost of goods sold

5.5 m11.4 m

Gross profit

(1.8 m)(2.3 m)

Gross profit Margin, %

(46%)(25%)

R&D expense

11.9 m12.2 m

General and administrative expense

7.5 m12.6 m

Operating expense total

19.4 m24.8 m

EBIT

(26.6 m)(76.4 m)

EBIT margin, %

(701%)(835%)

Interest expense

3.7 m6.9 m

Net Income

(30.8 m)(83.3 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

1.5 m221 k

Cost of goods sold

2.3 m1.7 m2.3 m4.6 m2.6 m2.4 m5.2 m12.2 m

R&D expense

2.1 m2.7 m2.3 m4.3 m2.9 m1.7 m3.7 m1.7 m4.1 m

General and administrative expense

1.7 m2.1 m3.6 m3.5 m3.1 m3.5 m3.3 m3.3 m7.1 m

Operating expense total

3.8 m4.8 m5.9 m7.8 m6.1 m5.3 m7 m5 m11.1 m

EBIT

(4.5 m)(7 m)(11.9 m)(24 m)(23.7 m)(15 m)(16.4 m)(14 m)(12.5 m)(25.8 m)

EBIT margin, %

(306%)(3156%)

Interest expense

884 k1 m961 k1.5 m2.1 m2.2 m2.4 m2.6 m2.2 m4.5 m

Net Income

(5.8 m)(9.4 m)(12.6 m)(26.5 m)(25.8 m)(17.1 m)(18.7 m)(16.3 m)(14.4 m)(29.6 m)

Neos Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016

Cash

90.8 m24.4 m

Accounts Receivable

1.2 m

Inventories

2.5 m5.8 m

Current Assets

98.2 m55.3 m

PP&E

5.1 m7.1 m

Total Assets

122.5 m80.1 m

Accounts Payable

4.8 m7.8 m

Short-term debt

8 m4.9 m

Current Liabilities

15.9 m21.6 m

Long-term debt

26.3 m58.6 m

Non-Current Liabilities

28.2 m60 m

Total Debt

34.2 m63.5 m

Total Liabilities

44.1 m81.7 m

Additional Paid-in Capital

195.3 m198.8 m

Retained Earnings

(116.8 m)(200.1 m)

Total Equity

78.4 m(1.5 m)

Debt to Equity Ratio

0.4 x-41 x

Debt to Assets Ratio

0.3 x0.8 x

Financial Leverage

1.6 x-51.8 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

25.6 m102.9 m42.4 m41.9 m43.5 m43.7 m57.4 m43.4 m24.8 m18.3 m

Inventories

1.7 m2.7 m2.5 m4.4 m5.7 m5.6 m6.1 m10 m13.4 m12.7 m

Current Assets

29.7 m106.4 m93.1 m91.9 m72 m74.7 m93.1 m87.9 m73.1 m60.1 m

PP&E

5.3 m5.2 m5.4 m6.8 m7 m7 m8.2 m8.2 m8.3 m

Total Assets

55.9 m131.1 m117.9 m117.7 m97.4 m99 m118.3 m113.2 m97.4 m84 m

Accounts Payable

1.3 m2.4 m3.5 m3.3 m7.8 m7 m8.3 m10.7 m10.7 m6.1 m

Short-term debt

5.8 m2.3 m1.7 m3.2 m7 m7 m6.9 m948 k16 m

Current Liabilities

7 m13.2 m17.9 m16.8 m21.4 m26 m30.6 m36.4 m40.2 m56.2 m

Long-term debt

31.2 m28.6 m31.8 m59 m59 m59 m59 m43.9 m

Non-Current Liabilities

37.6 m30.9 m33.5 m60.2 m60.1 m60.4 m62.4 m62.1 m61.7 m46.5 m

Total Debt

31.2 m34.4 m34.1 m1.7 m3.2 m66 m66 m65.9 m59.9 m59.9 m

Additional Paid-in Capital

5.1 m194.7 m195.9 m196.8 m197.8 m230 m261.4 m267 m275.6 m276.6 m

Retained Earnings

(98.1 m)(107.7 m)(129.4 m)(155.9 m)(181.7 m)(217.2 m)(235.9 m)(252.1 m)(279.7 m)(295 m)

Total Equity

(93 m)87 m66.4 m40.7 m15.9 m12.6 m25.3 m14.7 m(4.5 m)(18.6 m)

Debt to Equity Ratio

4.5 x

Debt to Assets Ratio

0.6 x

Financial Leverage

-0.6 x1.5 x1.8 x2.9 x6.1 x7.9 x4.7 x7.7 x-21.5 x-4.5 x

Neos Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016

Net Income

(30.8 m)(83.3 m)

Accounts Receivable

(2.2 m)

Inventories

2.5 m(3.2 m)

Accounts Payable

4.8 m3 m

Cash From Operating Activities

(70.6 m)

Cash From Investing Activities

(19.3 m)

Cash From Financing Activities

23.6 m

Interest Paid

2.9 m

Free Cash Flow

(74.2 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(5.8 m)(9.4 m)(12.6 m)(39.2 m)(65 m)(17.1 m)(35.8 m)(16.3 m)(14.4 m)(29.6 m)

Accounts Receivable

(2.8 m)(1.8 m)(360 k)(5.7 m)466 k(6 m)(4.3 m)

Inventories

1.7 m2.7 m19 k(1.9 m)(3.2 m)175 k(313 k)10 m(1.7 m)(981 k)

Accounts Payable

1.3 m2.4 m(1.4 m)(1.5 m)3 m(1.3 m)180 k10.7 m(1.2 m)(5.4 m)

Cash From Operating Activities

(13 m)(31.7 m)(50.8 m)(15.9 m)(22.3 m)(12.7 m)(21.2 m)

Cash From Investing Activities

(34.9 m)(41.4 m)(20 m)4.7 m(4.4 m)5.7 m8 m

Cash From Financing Activities

(451 k)24.2 m23.5 m30.6 m59.7 m(227 k)(451 k)

Interest Paid

687 k2.8 m2.8 m19 k2.2 m2 m4.1 m

Free Cash Flow

(13.7 m)(34.4 m)(53.9 m)(16.1 m)(24 m)(13 m)(22 m)

Neos Therapeutics Ratios

USDY, 2018

EV/EBIT

-8.3 x

EV/CFO

-10.1 x

EV/FCF

-9.7 x

Financial Leverage

-4.5 x
Report incorrect company information